Racial disparities in treatment use for multiple myeloma
Authors:
Open Access
Abstract
BACKGROUND: Recent treatment advances have greatly improved the prognosis of patients with multiple myeloma. However, some of these newer, more effective treatments are intensive and expensive and their use remains low, particularly among black patients.METHODS: In the current study, the authors reviewed the use patterns of stem cell transplantation and bortezomib using the Surveillance, Epidemiology, and End Results (SEER)‐Medicare linked database.RESULTS: After controlling for overall health and potential access barriers, black patients were found to be 37% (P<.0001) less likely to undergo stem cell transplantation, and 21% (P<.0001) less likely to be treated with bortezomib. Moreover, the authors found that the underuse of these treatments was associated with a 12% increase in the hazard ratio for death among black patients (P = 0.0007).CONCLUSIONS: Eliminating health disparities, a current focus of US public policy, is highly complex, as illustrated by the results of the current study. In patients with multiple myeloma, treatment disparities are not completely explained by potential access barriers. Additional factors, such as structural barriers in the health care system and individual decision making among black and white patients, must be explored to fully explain the disparity. Cancer 2017;123:1590–1596. © 2017 American Cancer Society.Keywords
This publication has 14 references indexed in Scilit:
- Prevalence, incidence and survival of smoldering multiple myeloma in the United StatesBlood Cancer Journal, 2016
- Re: Disparities in Utilization of Autologous Hematopoietic Cell Transplantation for Treatment of Multiple MyelomaTransplantation and Cellular Therapy, 2015
- Frontline therapy of multiple myelomaBlood, 2015
- Disparities in Utilization of Autologous Hematopoietic Cell Transplantation for Treatment of Multiple MyelomaTransplantation and Cellular Therapy, 2015
- Socioeconomic status is independently associated with overall survival in patients with multiple myelomaLeukemia & Lymphoma, 2015
- Addition of rituximab to chemotherapy alone as first-line therapy improves overall survival in elderly patients with mantle cell lymphomaBlood, 2011
- Racial disparities in incidence and outcome in multiple myeloma: a population-based studyBlood, 2010
- Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population.2002
- Development of a comorbidity index using physician claims dataJournal of Clinical Epidemiology, 2000
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987